Zusammenfassung
Eine prognostisch relevante Begleiterkrankung beim multiplen Myelom ist die kardiale AL-Amyloidose. Wir berichten über einen Patienten, dessen schwere Herzinsuffizienz bei kardialer AL-Amyloidose nach 2-maliger Hochdosismelphalantherapie mit jeweils anschließender autologer Blutstammzelltransplantation teilreversibel war, und bei dem eine partielle Rückbildung der myokardialen Amyloidablagerungen und Besserung der kardialen Funktion objektiviert werden konnten.
Abstract
Cardiac amyloidosis represents a prognostically relevant comorbidity in multiple myeloma. We report the case of a patient in whom severe heart failure symptoms as a consequence of cardiac AL-amyloidosis resolved after tandem high-dose melphalan therapy followed by autologous blood-stem cell transplantation. Partial regression of cardiac amyloid deposits and improvement of cardiac function were objectified.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Cooper LT, Baughman KL, Feldman AM et al. (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50: 1914–1931
Denz U, Haas PS, Wasch R et al. (2006) State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 42: 1591–1600
Gertz MA, Lacy MQ, Dispenzieri A (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 18: 17–37
Koyama J, Ray-Sequin PA, Falk RH (2003) Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107: 2446–2452
Kristen AV, Perz JB, Schonland SO et al. (2007) Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 9: 617–624
Kwong RY, Falk RH (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111: 122–124
Maceira AM, Joshi J, Prasad SK et al. (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111: 186–193
Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97: 341–344
Obici L, Perfetti V, Palladini G et al. (2005) Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 1753: 11–22
Perz JB, Rahemtulla A, Giles C et al. (2006) Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 37: 937–943
Sandstede JJ, Beer M, Hofmann S et al. (2000) Changes in left and right ventricular cardiac function after valve replacement for aortic stenosis determined by cine MR imaging. J Magn Reson Imaging 12: 240–246
Schaadt BK, Hendel HW, Gimsing P et al. (2003) 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 44: 177–183
Interessenkonflikt
Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morbach, C., Breunig, M., Weidemann, F. et al. 52-jähriger Patient mit schwerer Herzinsuffizienz bei multiplem Myelom. Internist 50, 225–229 (2009). https://doi.org/10.1007/s00108-008-2241-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-008-2241-6
Schlüsselwörter
- Kardiale Amyloidose
- Multiples Myelom
- Herzinsuffizienz
- 99mTc-Aprotininszintigraphie
- Magnetresonanztomographie